Sixth GAVI Board Meeting, 17 October 2001, Ottawa, Canada
confirmed that the availability of combination DTP-hepB and
DTP-hepB-Hib vaccines for 2002 had been reduced from 30 million to 20
million doses. It was estimated that this reduced quantity would be
sufficient for those countries that had already started the
introduction of these vaccines, but that no new countries would be
able to introduce combination DTP-hepB or DTP-hepB-Hib vaccines during
2002. The situation for 2003 would be clearer by end-2001.
also confirmed the relative scarcity of yellow fever vaccine during
2001 and that the priority had been to build up a 2 million dose
stockpile, in close collaboration with WHO and other partners in the
Inter-agency Consultative Group (ICG) that was set up to monitor
outbreak response. The stockpile had enabled immediate support to the
Côte dIvoire outbreak earlier this year. In addition, three countries
had received small quantities of vaccines based on GAVI approvals.
Availability for 2002 and beyond was considerably greater which would
enable good response to those countries applying for yellow fever
vaccine through GAVI.
welcomed the announcement made by Canada Minister for International
Cooperation Maria Minna that Canada would be contributing US $6.4
million ($10 million Canadian) to The Vaccine Fund over three years
and that the amount would be re-evaluated at the governments next
budget meeting in February 2002.
appreciated the presentation given by American Red Cross Senior
Technical Advisor Mark Grabowsky at the dinner preceding the Board
meeting, which outlined his organizations commitment to measles
teleconference to discuss the recommendations from the independent
review committee based on the 5th round of proposal review will be
held during the week of 26-30 November 2001.
meeting of the Board will be on 19-20 June 2002. Location still to be
determined, depending on the location of the Partners meeting later
in the year at least one of the Board meetings should be held in a
developing country. Suggestions for agenda items include:
reports from the field: Asia
of Vaccine Fund strategic plan
research & development
opening Window 3
progress on strengthening NGO involvement in GAVI
role of GAVI in middle-income countries
alignment with accelerated disease control initiatives
to allow for adequate consultation, documents for the next Board
meeting will need to be circulated well in advance.